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Yuji Shinzato1* and Yasukazu Ikehara2Abstract
The patient was a 27-year-old woman who was clinically diagnosed with tuberous sclerosis complex (TSC). She
developed hypercalcemia and hypophosphatemia at age 23. In a detailed examination at age 26, she was diagnosed
with primary hyperparathyroidism due to parathyroid adenoma. After undergoing parathyroidectomy, her
hypercalcemia and hypophosphatemia rapidly normalized. Subsequent genetic testing revealed mutations of
the TSC1 gene. TSC with concomitant parathyroid adenoma is extremely rare; only three cases have been
reported worldwide. However, each of these cases was diagnosed clinically. Therefore, our case is the first to be
diagnosed with genetic testing.
Keywords: Tuberous sclerosis complex, Primary hyperparathyroidism, Hypercalcemia, Hypophosphatemia,
Parathyroid adenoma, Neuroendocrine tumorsBackground
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant disorder that results from an inactivating mutation
in one of two genes, TSC1 (on chromosome 9q34), which
encodes hamartin, or TSC2 (on chromosome 16p13.3),
which encodes tuberin.
Hamartin and tuberin form a complex that regulates
cell proliferation and differentiation [1]. In TSC, hamar-
tomas and neoplastic lesions form at various sites
throughout the body. Lesions are often observed on the
central nervous system, eyes, skin, kidneys, heart, or
lungs; however, concomitant parathyroid adenoma is ex-
tremely rare and currently unreported in Japan. To date,
only three cases have been reported in the entire
world [2-4]. However, each of these cases was diag-
nosed clinically. Indeed, there is no reported case of
TSC that was diagnosed with genetic testing. Here, we
report our experience with a highly rare case of TSC
with concomitant primary hyperparathyroidism due to
parathyroid adenoma.* Correspondence: sinzato@cyutoku.or.jp
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Clinical course
The patient was a 27-year-old woman who began having
convulsive seizures at age 10. Her seizure types were
consistent with the following categories: generalized
tonic-clonic convulsion, absence seizure, and epileptic
automatism.
She was found to have cortical tubers, subependymal
nodules, retinal hamartoma, right ventricular cardiac
rhabdomyoma, white leaf-shaped macules on the right
thigh, and shagreen patches on the lower back. No in-
tellectual disability was present, and she had no family
history of TSC. She was clinically diagnosed with TSC.
Although her epilepsy was initially intractable, the at-
tacks eventually decreased and stopped occurring at
age 17. A cyst was discovered on the right kidney at
age 19, followed by multifocal micronodular pneumo-
cyte hyperplasia and hepatic hemangioma at age 26.
However, both were asymptomatic and did not show a
tendency toward enlargement; therefore, the patient’s
course is currently being observed while she receives
only sodium valproate.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Annual transitions in serum calcium and phosphorus
Age (years) 23 24 25 26
Ca (mg/dL) 10.7 10.9 11.3 11.5
P (mg/dL) 2.8 2.3 2.3 1.9
Albumin (g/dl) Not performed Not performed 4.3 4.4
Ca calcium, P phosphorous.
Shinzato and Ikehara World Journal of Surgical Oncology  (2015) 13:106 Page 2 of 5Hypercalcemia and hypophosphatemia developed and
gradually progressed from age 23, according to regular
annual testing (Table 1). She has shown no symptoms of
hypercalcemia, such as fracture or renal stone. Bone
mineral density (BMD) of the lumbar spine was normal
(T-score: −0.7) and renal function was also normal (cre-
atinine: 0.55 mg/dL). Thus, when the patient underwent
detailed examination at age 26, she was diagnosed with
asymptomatic primary hyperparathyroidism with in-
creased parathyroid hormone activity (intact PTH)
(Table 2). The results of tests of thyroid function, gas-
trin, insulin glucagon, vasoactive intestinal peptide, and
prolactin were all normal. Cervical ultrasonography
showed a mass shadow with a 1-cm diameter at a site
corresponding to the right inferior pole of the thyroid
gland. Technetium-99m methoxy-isobutyl isonitrile
(Tc99m MIBI) scintigraphy demonstrated accumulation
at the same site that had been identified through ultra-
sonography (Figures 1 and 2). She underwent minimally
invasive parathyroidectomy (PTx). The resected para-
thyroid adenoma weighed 0.3 g, and we observed
densely hyperplastic chief primary cells without fat
cells. No atypia or evidence of infiltration was seen. Al-
though a normal rim could not be observed, the sample
was considered a parathyroid adenoma based on the
enlargement of one gland (Figure 3). Following surgery,
the hypercalcemia, hypophosphatemia, and the plasma
intact PTH level rapidly normalized. These values
currently remain at normal levels, 1 year after PTx
(Table 3).
Previously, the patient had been clinically diagnosed
with TSC. At this point, we decided that a genetic test
should also be performed because new complications
had been found, such as parathyroid adenoma. In the
parathyroid adenoma, the TSC gene may have under-
gone loss of heterozygosity (LOH). A novel splicingTable 2 Endocrinological test findings
Serum laboratory studies Observed values Normal values
Intact PTH (pg/mL) 147 10–65
PTHrp (pmol/L) <1.1 0–1
1-25(OH)2D (pg/mL) 55 20–60
25(OH)D(ng/mL) 10.8 9–33.9
PTH parathyroid hormone, PTHrp parathyroid hormone-related protein-C, 1-25
(OH)2D 1,25-dihydroxyvitamin D3, 25(OH)D 25-hydroxyvitamin D.mutation was revealed by direct sequencing analysis of
the TSC1 gene extracted from peripheral blood. This
gene abnormality occurred at the location of an im-
portant consensus sequence of the splicing site, and
the probability of a gene splicing abnormality is high.
Thus, we surmised that the mutation might be patho-
genic (Figure 4). The results of the analysis of the
TSC2 gene were normal. Genetic testing was per-
formed by the Research Center for Bioscience and
Technology at Tottori University.Discussion
It is thought that the prevalence of TSC does not differ
according to region or race [5,6]. Exact data on the
prevalence of TSC in Japan are not available, but accord-
ing to a local investigation, the prevalence is estimated
to be at least about 1 in 6,000 persons. Thus, it is sup-
posed that there are about 15,000 patients with TSC in
Japan [6].
The incidence of primary hyperparathyroidism is con-
sidered to be 1 in 2,500 to 5,000 persons in Japan [7].
Asymptomatic cases, such as our case, are often de-
tected because of the increasingly common use of bloodFigure 1 Cervical ultrasonography. A mass shadow with a 1-cm
diameter at a site corresponding to the right inferior pole of the
thyroid gland.
Figure 2 Technetium-99m methoxy-isobutyl isonitrile (Tc99m MIBI) scintigraphy. This image shows accumulation at the same site that had
been identified through ultrasonography.
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and intact PTH.
TSC is an autosomal dominant disease that occurs
because of abnormalities in the TSC1 or TSC2 tumor
suppressor genes. Tumorigenesis in TSC is explained
by Knudson’s two-hit mutational mechanism [8]. The
first hit corresponds to a germline mutation inactivat-
ing one of the alleles of either TSC1 or TSC2, and the
second hit, called LOH, is a somatic mutation inacti-
vating the second allele [9,10]. In fact, LOH has been
confirmed in the development of multiple hamartomas
in a variety of organs and tissues in TSC patients
[9,11-13].
TSC1 encodes hamartin and TSC2 encodes tuberin.
TSC1 and TSC2 form a complex that regulates mam-
malian target of rapamycin (mTOR) activity in an in-
hibitory fashion. mTOR itself regulates cell growth and
proliferation [14]. Thus, it is believed that mTOR in-
creases if the hamartin-tuberin complex is functionally
impaired, resulting in dysplasia, tumor formation, and
angiogenesis due to accelerated cell proliferation, andFigure 3 Parathyroid adenoma resection sample. The sample weighed
cells. No atypia or evidence of infiltration is seen. Although a normal rim ca
based on the enlargement of one gland. A (Left): ×4; B (Right): ×10. Hemathereby causing the systemic manifestation of various
symptoms [10,15,16]. mTOR inhibitors have recently
been found to be effective for subependymal giant cell
astrocytoma, renal angiomyolipoma, and pulmonary
lymphangioleiomyomatosis, which are severe manifes-
tations of TSC [9,16,17].
Although cases of TSC rarely include concomitant
neuroendocrine tumors of the pituitary gland, parathy-
roid, pancreas, or adrenal gland, such cases have been
reported [3,18,19]. Because these cases are so infre-
quent, they tend to be viewed as coincidental. However,
there are confirmed cases of TSC2 gene LOH with pan-
creatic neuroendocrine tumors accompanying TSC
[18,19]. In addition, researchers investigating non-
familial pancreatic neuroendocrine tumors have re-
cently detected mutations of the TSC2 gene that affect
the mTOR pathway in a manner that is similar to the
mutations of phosphatase and tensin homolog deleted
on chromosome 10 (PTEN) and phosphatidylinositol-
4,5-bisphosphate 3-kinase, catalytic subunit alpha
(PIK3CA) [20]. Note that these TSC2 gene mutations0.3 g. We observed densely hyperplastic chief primary cells without fat
nnot be seen, the sample was considered a parathyroid adenoma
toxylin and eosin staining.
Table 3 Serum calcium, phosphorus, and PTH level after PTx
After PTx 1 day 2 weeks 1 month 3 months 6 months 1 year
Ca (mg/dL) 9.0 9.3 9.1 9.8 9.7 9.4
P (mg/dL) 2.5 3.3 2.7 2.5 2.5 3.3
Intact PTH (pg/mL) 9 43 42 27 38 39
Ca calcium, P phosphorus, PTH parathyroid hormone, PTx parathyroidectomy.
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crine neoplasia type 1 (MEN1) and death domain-
associated protein/alpha thalassemia/mental retardation
syndrome X-linked (DAXX/ATRX) gene mutations [20].
Therefore, neuroendocrine tumors are considered to
be possible complications of TSC. In the present case,
we attempted to investigate whether LOH had oc-
curred in the resected parathyroid adenoma tissue;
however, analysis was not possible due to the poor
state of the sample. Although there are no reports of
LOH of the TSC gene in parathyroid tissue, future
cases are expected.Figure 4 Gene analysis results. A novel splicing mutation in the TSC1 gen
in the patient.Conclusions
Our case suggests that it is possible for primary hyper-
parathyroidism to be complicated with TSC, even
though this presentation is extremely rare.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.e. Mutated and normal nucleotides (A and G, respectively) were present
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